KRAS and colorectal carcinoma: Similar results were obtained comparing mutant KRAS (HCT116, DLD-1) and wild-type KRAS (CACO-2) CRC cells under adherent (Fig. 4f) and non-adherent conditions (Supplementary Fig. 7f), suggesting that oncogenic KRAS increases the requirement for Cu bioavailability37.